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INTRODUCTION
Epithelial ovarian cancer (EOC) is the most lethal
of all gynecologic malignancies, and the fifth cause
of mortality. Women with organ-confined tumors
have an excellent prognosis, but the majority of
early stage cancer is asymptomatic, and more than
two-thirds (70-75%) of patients are diagnosed
with advanced disease and has often spread as dif-
fuse small-volume tumor deposits.1
A better understanding of ovarian cancer is ur-
gently needed for patients who currently present
with advanced disease requiring major surgery and
adjuvant chemotherapy, with the great majority
experiencing recurrence. Relapse occurs in the ma-
jority of advanced stage patients after complete re-
sponse to initial treatments; and at least 70-90%
of these patients eventually die with drug-resistant
cancers, with only 10-30% showing long-term sur-
vival. Despite many therapeutic improvements, the
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Objective: To evaluate fascin expression as a prognostic factor and
its correlation with survival and clinicopathologic factors (degree of
differentiation and stage) in epithelial ovarian carcinoma.
Methods: This study is prognostic study with historical cohort de-
sign. Fascin was analyzed in paraffin block sections of 33 advanced
stage ovarian carcinoma patients using immunohistochemistry. Fas-
cin expression was tested for its correlation with overall survival as
well as with grade and stage of the cancer.
Results: In this study, fascin expression has no correlation with sur-
vival. In the period of 17-22 months, samples with high fascin ex-
pression had a HR of 1.59 (95% CI=0.38-6.67, p=0.449), but in the
period of 17-23 months, both groups had comparable HR. In the pe-
riod of more than 23 months, samples with high expression of fascin
had a better HR of 0.40 (95% CI=0.04-4.38, p=0.449). No significant
correlation was found between fascin expression with grade
(OR=2.08, 95% CI=0.44-9.84, p=0.442) and stage (OR=2.70, 95%
CI=0.39-18.96, p=0.360).
Conclusion: In this study, there was no correlation between fascin
expression and survival, and also no correlation between fascin,
grade and stage. Further study with a larger, more homogenous
sample, analyzing confounding factors is needed.
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Abstrak
Tujuan: Melakukan penilaian terhadap hubungan ekspresi fascin se-bagai faktor prognostik kesintasan kanker ovarium stadium lanjut se-
cara umum, serta hubungan antara faktor klinikopatologis (derajat
diferensiasi dan stadium) pada khususnya.
Metode: Penelitian ini merupakan studi prognostik dengan desain ko-
hort retrospektif. Fascin dianalisa melalui 33 sampel blok paraffin dandilakukan pemeriksaan imunohistokimia. Data diperoleh dari status
medis, wawancara dengan pasien/keluarga atau melalui telepon.
Hasil: Pada periode 17-22 bulan, fascin dengan ekspresi tinggi me-
miliki HR=1,59 (IK 95%=0,38-6,67, p=0,449), tetapi pada periode 17-23 bulan, kedua kelompok memiliki hazard rasio yang sama. Pada pe-
riode lebih dari 23 bulan, fascin dengan ekspresi tinggi memiliki
HR=0,40 (IK 95%=0,04-4,38, p=0,449). Tidak terdapat korelasi ber-makna antara eksresi fascin dengan derajat diferensiasi dengan
OR=2,08 (IK 95%=0,44-9,84, p=0,442) dan stadium (OR=2,70, IK95%=0,39-18,96, p=0.360 ).
Kesimpulan: Didapatkan hasil yang tidak bermakna antara hasil ek-spresi fascin yang tinggi dengan kesintasan, serta tidak terdapat kore-
lasi bermakna antara ekspresi fascin dengan derajat diferensiasi.
Diperlukan penelitian lebih lanjut dengan jumlah sampel yang lebihbesar dan lebih homogen, dengan menganalisa faktor-faktor perancu
yang dapat ditemui.
[Maj Obstet Ginekol Indones 2015; 3-4: 222-229]
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development of secondary metastatic tumors that
are resistant to conventional treatment remains a
major cause of morbidity and mortality.1,2 Tumor
invasion and metastasis are the result of highly co-
ordinated processes involving multiple intracellu-
lar and extracellular factors. Understanding the
early events that enable carcinoma cell migration
and invasion is an important research goal that has
the potential to improve early diagnosis of aggres-
sive tumors and stimulate new approaches to-
wards molecular adjuvant therapies. Carcinoma
cell migration is facilitated by the altered differen-
tiation status of the epithelial cells, including
changes in cell and cell matrix adhesion properties
and in the organization of the actin cytoskeleton.
The cytoskeleton is a complex network that in-
cludes three types of protein: actin filaments, mi-
crotubules and intermediate filaments. Changes in
cytoskeletal components or associated binding
proteins may be implicated in the progression and
metastasis of tumors.
Fascin is a globular actin cross-linking protein
that has a major function in forming parallel actin
bundles in cell protrusions that are key specializa-
tions of the plasma membrane for environmental
guidance and cell migration. Fascin is a highly con-
served actin-bundling protein, widely expressed in
mesenchymal tissues and the nervous system, and
is low or absent in adult epithelium. Recent data
from a number of studies have highlighted that fas-
cin is up-regulated in many human carcinomas and
in individual tissues, correlating with the clinical
aggressiveness of tumors and poor patient sur-
vival. In cell culture, over-expression or depletion
of fascin modulates cell migration and alters cy-
toskeletal organization. The identification of bio-
markers to provide more effective early diagnosis
of potentially aggressive tumors, or identify tumors
susceptible to targeted therapies, is an important
goal in clinical research.3-8
There were many studies on fascin that showed
correlation between fascin and malignancy. Da-
ponte reported that strong fascin immunoreactivi-
ty was associated with poor prognosis; patients
with low fascin expression had a median survival
of 36.5 months versus 32 months for high fascin
expression (p=0.041), and the median PFl was 24
versus 17.5 months, respectively (p=0.034). Fascin
expression is an independent prognostic factor for
survival of advanced ovarian serous carcinoma,
and may represent a novel therapeutic target for
patients with aggressive forms of ovarian cancer.9
Eun et al reported that fascin expression was de-
tected in the majority of borderline (100%, 32/32)
and malignant tumors (90.5%, 67/74), but it was
not seen in normal ovarian surface epithelial cells
and benign tumors (p<0.001). Fascin expression
was significantly correlated with the occurrence of
peritoneal metastases in the carcinomas (p=
0.043).10 Fascin overexpression has an important
role in invasiveness and recurrence of uroephi-
telial malignancy. There were significant numbers
of fascin-1-positive cells (50% of the neoplastic
cells) in uroepithelial carcinomas in situ (n=10).
These findings suggest an association between in-
creased fascin-1 expression and increased inva-
siveness of carcinomas in the urinary bladder.11
The aim of this study is to evaluate the correla-
tion between fascin expression, survival and clini-
cophatologic factors in advanced stage ovarian car-
cinoma. Fascin has emerged as a very interesting
candidate for biomarker because its expression is
low or absent in the majority of normal adult epi-
thelium, yet up-regulation of the protein has been
reported in many forms of human carcinoma.
Irrespective of the tissue source of the tumor, high
levels of fascin expression in primary carcinomas
has been consistently correlated with a clinically
aggressive phenotype and poor prognosis.9
METHODS
This study is prognostic study with historical co-
hort design. Thirty-three patients with a diagnosis
of advanced stage epithelial ovarian carcinoma
(91% were stage III and 9% were stage IV) who
received postoperative chemotherapy (TC: 175
mg/m2 paclitaxel and carboplatin after calculating
the area under the concentration curve) were in-
cluded in this study. Due to limited sample, only
23 patients had complete cycles (6 cycles). The pa-
tients who had complete medical records were se-
lected for further analysis. Patients were examined,
diagnosed and underwent therapy in the Gyneco-
logic Oncology Division, Obstetrics and Gyneco-
logy Department, RSCM, Jakarta.
Pathological samples from paraffin-embedded
tissue from each of the above patients were in-
cluded in this study. Clinicopathologic information
was obtained from medical records. Cancer pa-
tients were classified after a staging laparotomy;
the most common initial surgical procedure con-
sisted of abdominal hysterectomy, bilateral salphy-
ngo-oophorectomy, omentectomy, and pelvic and
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paraaortic lymph node dissection. The surgery was
classified as complete resection when no macros-
copic tumor remained. Surgical procedures were
carried out in the Division of Gynecologic Oncology,
University of Indonesia. All slides were reviewed
by the pathologists.
Survival analysis was performed after the pa-
tients were dichotomized according to a fascin im-
munohistochemistry score of <3 and ≥3. The opti-
mal cutoff point of fascin expression based on im-
munohistochemistry was calculated in conside-
ration of sensitivity and specificity of ROC curve
analysis for the survival. This research started at
September 2013 until October 2014, with samples
being taken from 2006. At the time of analysis, 11
of the 33 patients were deceased due to their dis-
ease.
Immunohistochemical staining of ovarian tissue
was performed in a commercially available auto-
mated immunostainer. The samples were fixed in
10% buffered formalin solution, embedded in pa-
raffin blocks and cut at 4 mm sections. For fascin
expression, slides were incubated for 20 minutes
at room temperature with clone IM20 (Novocastra,
Newcastle upon Tyne, UK) diluted to 1:300.
All slides were initially evaluated by a patholo-
gist. During a subsequent joint evaluation, a final
consensus of immune reactivity score was ob-
tained and used for statistical analysis. Cytoplasmic
immune reactivity of tumor cells was assessed in
comparison with tonsil specimen, which was used
as positive controls. Two aspects of immune reac-
tivity were semi-quantitatively evaluated: the ex-
tent and the intensity of staining. Intensity was
considered as "weak to moderate" when it was less
than that of tonsillar tissue and "intense" when it
was similar to that of the tonsil. After preliminary
analysis, the pathologists involved in the evalua-
tion of immunohistochemical staining realized that
the observed differences in immunoreactivity were
best represented by counting only the cellular sub-
population showing intense immunohistochemical
staining and expressing this as the HIES (highest
immunohistochemical expression score). To calcu-
late HIES, a value from 0 to 4 was assigned accord-
ing to the percentage of cells showing intense
staining (0: 0%, 1: <25%, 2: 25-50%, 3: 50-75%;
4: >75%).
Univariate analysis of categorical variable will be
presented in percentages and frequencies. Overall
survival was defined as the interval from the date
of surgery to death from ovarian carcinoma or at
the end of the study period on 27th October 2014.
Correlation between fascin expression and survival
will be tested using Kaplan Meier Method, Cox Re-
gression and Life Table. Bivariate analysis of cor-
relation between fascin expression and clinico-
pathologic characteristics, will be analysed using
Fisher test. SPSS software v.22.0 for Mac was used
for the statistical analysis, p<0.05 was considered
to be statistically significant.
RESULTS
We included 33 tissue samples of patients with
EOC. Our sample had an average age of 49.95 years,
39.4% in the age group of 40-49 years. Only 20
patients (60.0%) had optimal debulking surgery
with complete resection (no macroscopic residual
disease), and 39.4% had residual tumor more than
2 cm in diameter. In terms of histologic type, 17
patients (51.5%) had serous EOC, 9/33 had clear
cell carcinoma, 4/33 had endometrioid, and 3/33
had mucinous type EOC, with 6/33 patients having
well differentiated tumors, and 25/33 had mode-
rate-poor differentiated tumors.
Following assessment of fascin immunoreacti-
vity, 14 (42.4%) tumor samples were classified as
having low fascin expression (immunohistoche-
mistry score <3) and 19 (57.6%) having high fas-
cin expression (immunohistochemistry score ≥3).
The cutoff point was determined from the sen-
sitivity and specificity analysis and ROC curve
analysis to survival. We found that the cutoff IRS
Table 1. Correlation between Fascin Expression and Survival
Time Variable Coefficient SE Wald df value p HR
95% CI
Min Max
0-17 months Fascin ≥3 0.461 0.733 0.396 1 0.529 1.59 0.38 6.67
>23 months Fascin ≥3 -0.929 1.229 0.572 1 0.449 0.39 0.04 4.39
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score was 3 with sensitivity of 54.5% and specifi-
city of 40.9% with AUC=0.450 (95% CI=0.240-
0.661).
Figure 1. Kaplan Meier Curve Associated with Fascin Ex-
pression
Table 2. Correlation between Fascin Expression and Grading
Moderate­poor differentiation Well differentiation
p­value OR (95% CI)
n % n %
IRS Score Positive (≥3) 15 78.9 4 21.1 0.442 2.08 (0.44-9.84)
Negative (<3) 9 64.3 5 35.7
Table 3. Correlation between Fascin Expression and Stage
Stage 4 Stage 3
p­value OR (95% CI)
n % n %
IRS Score Positive (≥3.75) 3 23.1 10 76.9 0.360 2.70 (0.39-18.96)
Negative (<3.75) 2 10.0 18 90.0
IRS Score Positive (≥3) 3 15.8 16 84.2 1.000 1.13 (0.16-7.82)
Negative (<3) 2 14.3 12 85.7
Figure 2A. Clear cell carcinoma with immunostaining for
fascin. Note low cytoplasmic staining, negative intensity.
IRS score : 0
Figure  2B. Serous adenocarcinoma with immunostain-
ing for fascin. Note moderate cytoplasmic staining, mo-
derate intensity, IRS score : 8
Figure 2C. Serous adenocarcinoma grade 1 with immu-
nostaining for fascin. Note strong cytoplasmic staining,
strong intensity, IRS score : 5.5
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Among 33 samples, 11 patients were deceased
due to their disease, and 22 (64.7%) were still alive
at the end of the study. There were cutoff points in
the period of 17 months and 22 months. In the pe-
riod of month 17-22, samples with high fascin ex-
pression had a HR of 1.59 (95% CI=0.38-6.67,
p=0.449), but in the period of month 17-23 both
groups had comparable HR. In the period of more
than 23 months, group with high fascin expression
had a better HR of 0.40 (95% CI=0.04-4.38, p=0,449).
This is presented in Figure 1 and Table 1.
The sensitivity and specificity analysis and ROC
curve analysis for tumor grading showed an opti-
mal cutoff point for fascin expression to be ≥3 with
sensitivity of 62.5% and specificity of 55.6%, AUC=
0.525 (95% CI=0.307-0.744); p=0.824. The propor-
tion of samples with high fascin expression and
moderate-poor differentiation was 78.9%, com-
pared with the well differentiated being only
21.1%. Meanwhile, proportion of samples with low
fascin expression and moderate-poor differentia-
tion was 64.3%, compared with those that are well
differentiated being only 35.7%.
The ROC curve analysis for the staging, had an
optimal cutoff point of 3.75 with sensitivity and
specificity of 60% and 64.2%, with AUC of 0.607
(95% CI=0.329-0.885, p=0.451). High fascin ex-
pression in stage four EOC was 23.1%, compared
with stage three EOC which was 76.9%. Mean-
while, low fascin expression in stage four EOC was
only 10%, while in stage three EOC was 90%.
DISCUSSION
Ovarian cancer is the most common cause of gyne-
cological cancer-related mortality. Patients with
this disease generally undergo surgery followed by
platinum-taxane chemotherapy (TC), with addi-
tional chemotherapy at occurrence of relapse. Al-
though the prognosis for patients with advanced
cancer is poor, with a five-year survival of only 30-
40%, there is a wide range of outcomes for indi-
vidual patients. Clinicopathological variables such
as staging, grading, histological type, debulking
status, and response to chemotherapy continue to
provide the basis on which treatment decisions are
made for individual patients. Additional biomark-
ers in cancer tissues need to be extensively evalu-
ated to improve individualized therapy for pa-
tients.9
Fascin has emerged as a prognostic marker in
some carcinomas. In this study, we examined ova-
rian neoplasms to confirm the presence of any cor-
relation between fascin expression and established
clinicopathologic parameters.12
Fascin is a 55 kDa globular protein that orga-
nizes F-actin into well-organizeded, tightly packed
parallel bundles in vitro and in cells. Fascin have
been well conserved in animal evolution: homo-
logues are present in Drosophila, echinoderms and
the platyhelminth Schmidtea mediterranea. Verte-
brate genomes encode three forms of fascin: fas-
cin-1, which is widely expressed by mesenchymal
tissues and in the nervous system; fascin-2, which
is expressed by retinal photoreceptor cells; and fas-
cin-3, which is testis-specific. The focus of this ar-
ticle is on fascin-1 (also known as fascin), which
contributes to the organization of two major forms
of actin-based structures: cortical cell protrusions
that mediate cell interactions and migration, and
cytoplasmic microfilament bundles that contribute
to cell architecture and to intracellular move-
ments.13
Cell motility is one of the defining characteristics
of invasive tumors, enabling tumor cells to migrate
into adjacent tissues or through the basement
membranes and extracellular matrices. The initial
step in cell migration is the protrusion of the cell
membrane. This is driven by localized actin poly-
merization. Reorganization of the actin cytoskele-
ton is the primary mechanism of cell motility and
is essential for most types of cell migration. Inva-
sive tumor cells have been demonstrated to present
dysregulated cell motility in response to extracellu-
lar signals from growth factors and cytokines.14
A key structural requirement for cell protrusion
is the need for a rigid cytoskeletal structure to sup-
port the localized extension of the plasma mem-
brane with its characteristic morphology. This is
achieved in finger-like protrusions by a central,
unipolar bundle of filamentous actin (F-actin) and
in lamellipodial protrusions by radial, rib-like actin
bundles that are integrated with a dendritic mesh-
work of microfilaments. Fascin-1 is known to be
the core actin bundling protein of dendrites, mi-
crospikes, filopodia, and lamellipodial ribs, and to
be concentrated in cell protrusions during cell mi-
gration. Fascin-1 contributes to the formation of
various actin-based cellular structures.13,15,16
Among those, and critical in cancer cell biology, are
the cellular surface protrusions that mediate cell
Indones J
226  Vitranti et al Obstet Gynecol
|
movement. In vitro studies, based on transfection
experiments, have shown that elevated levels of
fascin increased the speed of cell migration and
emphasized the association between fascin expres-
sion and motility of transformed cells.15
Metastatic and invasive tumor cells often exhibit
changes in cell morphology, disruption of cell-cell
contacts, degradation of ECM and increase in cell
migration, which result from rearrangements of
the cytoskeletal microfilaments. Reorganization of
the actin cytoskeleton is regulated by the action of
actin crosslinking proteins. Fascin expression is
either low or absent in adult epithelia and is often
up-regulated in several types of epithelial cancers
including breast, ovarian, skin, pancreatic, liver,
esophageal squamous cell, urothelial carcinoma,
glioblastoma and cervical cancer.3,14,17-19
A number of prior studies have shown that fas-
cin up-regulation is associated with a more aggres-
sive and metastatic phenotype in epithelial cancers.
Several correlative studies have demonstrated the
tumor promoting function of fascin, its role in tu-
mor development and/or progression of ovarian
cancer is yet to be comprehensively investigated.
Meta-analyses demonstrate that there is strong
evidence that fascin-1 protein is associated with an
up to two-and-a-half-fold increased risk of mortali-
ty in breast, colorectal, and esophageal carcinomas.
At present, there is little evidence that fascin-1 is
associated with mortality for gastric and lung car-
cinomas. Fascin-1 is correlated with an increased
risk of disease progression in breast and colorectal
carcinomas, but not in lung carcinoma. Strong evi-
dence for association of fascin-1 with increased
risk of lymph node metastasis has been observed
for colorectal and gastric carcinomas, but not for
lung and esophageal carcinomas. Fascin-1 protein
was also associated with a greater than 70% in-
creased risk of distant metastasis in colorectal, gas-
tric, and esophageal carcinomas, although the sta-
tistical evidence for association with esophageal
carcinoma metastasis was weak. Pooled analysis of
all carcinomas within our dataset provides strong
evidence that fascin-1 may carry the potential as a
novel biomarker for early identification of aggres-
sive and metastatic tumors. These data will assist
rational decision-making for focusing ongoing ef-
forts investigating fascin-1 as a biomarker for the
most relevant carcinoma.20
In general, fascin overexpression has been asso-
ciated with invasive, high-grade tumors. Recently,
however, Yamaguchi et al have reported over-
expression of fascin and up-regulation of fascin
mRNA in intraductal papillary mucinous neo-
plasms of pancreas that correlated with increasing
histologic grade (adenoma, borderline neoplasm,
and carcinoma with or without invasion) suggest-
ing fascin up-regulation as an early event in the
pathogenesis of pancreatic mucinous intraductal
papillary neoplasms.21 Down regulation of fascin
has been shown to have inhibitory effects on the
migration, proliferation, and invasiveness of eso-
phageal squamous cell carcinoma cell lines, sug-
gesting that fascin contributes to tumor progres-
sion and could possibly be a therapeutic molecular
target.22
Kabukcuoglu et al studied fascin expression in
ovarian tumors (serous, endometrioid, clear, muci-
nous, mixed, and transitional) and found various
degrees of epithelial staining in 20% of cystade-
noma, 62% of borderline tumors, and 64% of in-
vasive epithelial ovarian tumors.19,23 Hu et al have
also shown increased expression of fascin in cell
cultures derived from stage IV ovarian tumors ver-
sus cell cultures derived from stage II-III ovarian
tumors. They also shown that the expression of fas-
cin in ovarian tumor cell cultures is significantly
associated with their ability to grow and spread in-
traperitoneally after intraperitoneal inoculation,
supporting the role of fascin in ovarian tumor me-
tastasis.19 It was also observed that there was in-
creased expression of fascin in paraffin-embedded
sections from borderline ovarian tumors, whereas
they did not see any expression of fascin in benign
ovarian epithelium. Fascin up-regulation in human
breast cancer cell lines has been associated with
HER-2 overexpression, which is associated with
poor prognosis in breast cancer. HER-2 is often
positive in serous ovarian tumors as well, and its
association with fascin up-regulation can be a sub-
ject for further investigation.22
In our study, we characterized fascin protein ex-
pression in a series of advanced stage epithelial
ovarian carcinoma by immunohistochemistry. Fi-
gure 1 shows that survival in groups with fascin
expression ≥3 and fascin expression <3 crossed in
the periode of 17 months to 22 months. Between
0-17 months, subject with fascin expression ≥3 has
worse HR of 1.59 (95% CI=0.38-6.67, p=0.449).
However, between 17-23 months, both of the
group have same hazard. After 23 months, higher
fascin expression had a better hazard with HR of
0.40 (95% CI=0.04-4.38).
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Previous studies have implicated fascin as a
novel biomarker for human carcinomas and ag-
gressive tumor behavior. In our study, statiscally
these findings were not significant and it could be
due to the heterogenicity and limited sample of this
research.
In tissues with positive expression of fascin, up
to 78.9% had moderate-poor differentiation, which
was higher than those that are well differentiated,
which was 21.1%. Statistically this is not signifi-
cant, but the difference between positive and nega-
tive fascin expression is clinically significant. Posi-
tive expression of fascin in stage 4 EOC is 23.1%,
compared with stage 4 in the negative expression
group, which was only 10%. Nevertheless, this was
not statistically significant.
The cadherin family of trans membrane glyco-
proteins is important for cellular adhesion in epi-
thelial cells. It is known that E-cadherins mediate
homotypic adhesions in epithelial tissues and serve
to keep the epithelial cells together.24 Ying et al
suggested that fascin and cadherin binding sites
within β-catenin overlaps; and that, in vitro, fascin
and cadherins compete for binding to β-catenin in
transformed epithelial cell systems.25 Yamashiro et
al observed that transfection of the fascin gene
leads to cell-to-cell contact disorganization and in-
creased cell motility by inducing the emission of
microspikes on apical surfaces and on the extended
lamelipodia on basolateral surfaces. Some of these
changes are due to the downregulation and altered
cytoplasmic distribution of the E-cadherin based
adhesion complex induced by fascin over expres-
sion.26 E-cadherin is the key functional compo-
nent of adherent junctions between epithelial cells.
Downregulation of E-cadherin in several types of
human neoplasms usually correlates with poor tu-
mor differentiation, more advanced disease stage,
lymph node metastases, and poor survival rates. A
relationship between fascin and E-cadherin has
been documented, where cytoplasmic accumula-
tion of fascin leads to a loss of cell-to-cell adhesion
by disruption of the E-cadherin adhesion system.24
This agrees with findings of Okada et al who
showed that increased immunoreactivity for fascin
had a tendency to disrupt membranous immunore-
activity for E-cadherin. Therefore, it may be postu-
lated that the altered expression of E-cadherin is
involved in fascin mediated cell motility.27
CONCLUSION
In conclusion, we have found an association bet-
ween fascin expression and survival, as well as
clinicopathologic properties (grade and stage) in
epithelial ovarian cancer. However, the association
was not statistically significant. Confounding bias
(sample is heterogenous) and sample bias (small
number of sample) could be the reason why these
results were not significant. Further studies with a
larger, more homogenous sample, with analysis of
the confounding factors are required.
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